You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/39901
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBolon, Brad-
dc.contributor.authorBarale-Thomas, Erio-
dc.contributor.authorBradley, Alys-
dc.contributor.authorEttlin, Robert A.-
dc.contributor.authorFranchi, Carla Adriene da Silva-
dc.contributor.authorGeorge, Catherine-
dc.contributor.authorGiusti, Anna Maria-
dc.contributor.authorHall, Robert-
dc.contributor.authorJacobsen, Matthew-
dc.contributor.authorKonishi, Yoichi-
dc.contributor.authorLedieu, David-
dc.contributor.authorMorton, Daniel-
dc.contributor.authorPark, Jae-Hak-
dc.contributor.authorScudamore, Cheryl L.-
dc.contributor.authorTsuda, Hiroyuki-
dc.contributor.authorVijayasarathi, S. K.-
dc.contributor.authorWijnands, Marcel V. W.-
dc.date.accessioned2014-05-20T15:30:33Z-
dc.date.accessioned2016-10-25T18:06:06Z-
dc.date.available2014-05-20T15:30:33Z-
dc.date.available2016-10-25T18:06:06Z-
dc.date.issued2011-01-01-
dc.identifierhttp://dx.doi.org/10.1016/j.etp.2010.07.006-
dc.identifier.citationExperimental and Toxicologic Pathology. Jena: Elsevier Gmbh, Urban & Fischer Verlag, v. 63, n. 1-2, p. 187-195, 2011.-
dc.identifier.issn0940-2993-
dc.identifier.urihttp://hdl.handle.net/11449/39901-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/39901-
dc.description.abstractThe International Federation of Societies of Toxicologic Pathologists (IFSTP) proposes a common global framework for training future toxicologic pathologists who will support regulatory-type - nonclinical toxicology studies. Trainees optimally should undertake a scientific curriculum of at least 5 years at an accredited institution leading to a clinical degree (veterinary medicine or medicine). Trainees should then obtain 4 or more years of intensive pathology practice during a residency and/or on-the-job "apprenticeship," at least 2 years of which must be focused on regulatory-type toxicologic pathology topics. Possession of a recognized pathology qualification (i.e., certification) is highly recommended. A nonclinical pathway (e.g., a graduate degree in medical biology or pathology) may be possible if medically trained pathologists are scarce, but this option is not optimal. Regular, lifelong continuing education (peer review of nonclinical studies, professional meetings, reading, short courses) will be necessary to maintain and enhance one's understanding of current toxicologic pathology knowledge, skills, and tools. This framework should provide a rigorous yet flexible way to reliably train future toxicologic pathologists to generate, interpret, integrate, and communicate data in regulatory-type, nonclinical toxicology studies. (C) 2010 Reprinted by Permission of SAGE Publications Inc. Published by Elsevier GmbH. All rights reserved.en
dc.format.extent187-195-
dc.language.isoeng-
dc.publisherElsevier Gmbh, Urban & Fischer Verlag-
dc.sourceWeb of Science-
dc.subjectToxicologic pathologistsen
dc.subjectEducationen
dc.subjectTrainingen
dc.subjectExperienceen
dc.subjectRegistrationen
dc.subjectAccreditationen
dc.subjectRecognitionen
dc.titleInternational recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studiesen
dc.typeoutro-
dc.contributor.institutionGEMpath Inc-
dc.contributor.institutionCharles River Labs-
dc.contributor.institutionEttlin Consulting Ltd-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionIpsen-
dc.contributor.institutionAccelera-
dc.contributor.institutionCovance Labs-
dc.contributor.institutionAstraZeneca-
dc.contributor.institutionNovartis Pharma AG-
dc.contributor.institutionPfizer-
dc.contributor.institutionSeoul Natl Univ-
dc.contributor.institutionUniv London Royal Vet Coll-
dc.contributor.institutionNagoya City Univ-
dc.contributor.institutionAdvinus Therapeut Pvt Ltd-
dc.contributor.institutionMerck Sharp & Dohme Ltd-
dc.contributor.institutionJohnson & Johnson PRD-
dc.description.affiliationGEMpath Inc, Longmont, CO USA-
dc.description.affiliationCharles River Labs, Edinburgh, Midlothian, Scotland-
dc.description.affiliationEttlin Consulting Ltd, Muenchenstein, Switzerland-
dc.description.affiliationUniv Estadual Paulista, UNESP, Paulista, Brazil-
dc.description.affiliationIpsen, Les Ulis, France-
dc.description.affiliationAccelera, Nerviano, Italy-
dc.description.affiliationCovance Labs, Madison, WI USA-
dc.description.affiliationAstraZeneca, Macclesfield, Cheshire, England-
dc.description.affiliationNovartis Pharma AG, Basel, Switzerland-
dc.description.affiliationPfizer, Groton, CT USA-
dc.description.affiliationSeoul Natl Univ, Seoul, South Korea-
dc.description.affiliationUniv London Royal Vet Coll, Hatfield, Herts, England-
dc.description.affiliationNagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan-
dc.description.affiliationAdvinus Therapeut Pvt Ltd, Bangalore, Karnataka, India-
dc.description.affiliationMerck Sharp & Dohme Ltd, Oss, Netherlands-
dc.description.affiliationJohnson & Johnson PRD, Beerse, Belgium-
dc.description.affiliationUnespUniv Estadual Paulista, UNESP, Paulista, Brazil-
dc.identifier.doi10.1016/j.etp.2010.07.006-
dc.identifier.wosWOS:000286779300027-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofExperimental and Toxicologic Pathology-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.